AB0798 AMTOLMETIN GUACIL-EFFECTIVE AND GOOD SAFE NONSTEROIDAL ANTI-INFLAMMATORY DRUG IN KNEE OSTEOARTHRITIS PATIENTS WITH DYSPEPSIA
Objectives: To investigate the efficacy and tolerability of amtolmetin guacil (AMG; Niselat ® , Dr. Reddy's Laboratories Ltd, India) versus previous therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with knee osteoarthritis (OA) and signs of dyspepsia.
Methods:
The open-label observational study included 220 patients aged 30-65 years who suffered from knee OA and intense pain during NSAID intake and had symptoms of dyspepsia in the absence of contraindications to the use of AMG. Among the comorbidities that generally occurred in 68% of the patients, there was a preponderance of hypertension (42%), lower extremity varicose veins (6.4%), and diabetes mellitus (6%). Treatment efficacy was evaluated using three domains of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), by also taking into account pain intensity and general health assessment on the visual analogue scale. A Severity of Dyspepsia Assessment (SODA) scale was used to rate dyspepsia. Results: AMG had a marked analgesic effect confirmed by 40% or more pain reduction thatoccurred in 72.5% of the patients. The high analgesic effect of AMG was confirmed by a statistically significant (p<0.001) reduction in the WOMAC index (pain and stiffness) and by an increase in functional activity. Therewas a significant decrease in painless and painful signs of dyspepsia, as well as positive changes in the measures"overall assessment of dyspepsia severity" (p<0.001) and "satisfaction with treatment". Overall assessment ofAMG tolerability was only positive: excellent (33%), good (56%), and satisfactory (11%). There were no seriousadverse events (AE). AE were graded as moderate and mild in 8 and 82% of cases, respectively. AE were recordedin 7.7% of the patients. AMG had a marked analgesic effect confirmed by 40% or more pain reduction that occurred in 72.5% of the patients. The high analgesic effect of AMG was confirmed by a statistically significant (p<0.001) reduction in the WOMAC index (pain and stiffness) and by an increase in functional activity. There was a significant decrease in painless and painful signs of dyspepsia, as well as positive changes in the measures "overall assessment of dyspepsia severity" (p<0.001) and "satisfaction with treatment". Overall assessment ofAMG tolerability was only positive: excellent (33%), good (56%), and satisfactory (11%). There were no serious adverse events (AE). AE were graded as moderate and mild in 8 and 82% of cases, respectively. AE were recorded in 7.7% of the patients. Background: Progression of osteoarthritis (OA) produces loss of articular cartilage that may culminate in pain, loss of joint function, and disability. Osteoarthritic changes in articular cartilage are associated with progressive proteolytic degradation of the extracellular matrix due to excessive expression of metalloproteinases (MMPs) over their tissue inhibitors (TIMPs). At the same time, decrease in TIMP concentration versus MMP has been previously associated with an increase in pain sensitivity. Objectives: Here we hypothesized that imbalance in TIMP1 and MMP-9 gene and protein expressions in the peripheral blood might contribute to pain perception in OA patients. Methods: We examined whole blood of 65 OA outpatients and 27 healthy subjects. Clinical testing comprised physical examination, radiographic and WOMAC scoring, and ultrasonography. Total RNA isolated from the whole blood was used for gene expression examination of mTOR, mechanistic target of rapamycin, a major regulator of cell growth and proliferation, metalloproteinase MMP-9, and tissue inhibitor of metalloproteinase, TIMP1 using quantitative Realtime RT-PCR. p70-S6K (mTOR read-out), MMP-9, and TIMP1 protein levels were quantified by ELISA. Results: 23 OA outpatients exhibited significant downregulation of mTOR gene expression (subset "Low mTOR") while other 42 OA outpatients have demonstrated upregulation of mTOR gene expression (subset "High mTOR") in the peripheral blood compared to healthy controls. Although both OA outpatient subsets had comparable radiographic severity according to Kellgren-Lawrence grading, similar age, disease duration, and body mass index, "Low mTOR" patients experienced significantly higher pain at joint function versus "High mTOR" subset. This was associated with a significant upregulation of MMP-9 gene expression in "Low mTOR" patients versus healthy subjects while TIMP1 expression remained equal to controls. In a "High mTOR" subset, both gene expressions were significantly upregulated. p70-S6K and TIMP1 protein concentrations measured in the peripheral blood mononuclear cells were significantly lower in "Low mTOR" patients versus that in "High mTOR" while MMP-9 protein expression was significantly higher compared to healthy subjects in both examined OA subsets. Conclusions: Our results show that TIMP1 and MMP-9 gene expressions measured in the peripheral blood might be associated with pain sensitivity in OA outpatients while low level of TIMP1/MMP-9 ratio indicates increased pain perception. Background: Knee osteoarthritis (KOA) is the most common form of arthritis with an estimated lifetime prevalence of 44.7% (1). The use of orthotic devices (knee braces, insoles, wedged shoes) is a generally accepted conservative therapy for KOA patients (2). However, it is suggested that their effectiveness is detrimentally affected by poor patient compliance due to discomfort while wearing these devices (3). Objectives: The aim of this study is to objectively establish the compliance to an orthotic intervention using a thermal sensor (TS) and comparing it to patients' self-reported wear time. Methods: Ten medial KOA patients (mean±SD age 57.6±13.4 years, BMI 27.3±3.2 kg/m 2 ), clinically diagnosed according to the ACR Guidelines, were recruited for this study. A small, light-weight TS with the size of an average lithium battery (0.5°C resolution) was placed in a newly developed ankle-foot-orthosis (AFO) that patients were asked to wear as often as possible during a period of six weeks. The TS measured the temperature every 5 minutes for 4 weeks. Patients rated the comfort of the orthosis during the first visit using a scale from 1 to 5 (1 being the most comfortable). Additionally, the patients reported during these six weeks how many hours per day they had worn the orthosis and rated which amount of pain they felt each day (from 0=no pain to 10=most painful). To determine the patients' compliance, the AFO wear time, derived from the TS, was compared to the wear time per day recorded in the patients' diaries. The threshold to differentiate the wear and non-wear times was set at 25°C. Timeframes during which the temperature rose above 25°C were classified as wear time. A Wilcoxon signed-rank test was performed between the different wear times and Spearman's correlations between pain, comfort and wear time were determined. Results: On average, patients wore the device for 143±80 h according to the form they filled out, whereas the TS measured only 83±86 h, leading to an overestimation of 72%. Patients reported an average pain level of 3±1.4 during the six weeks period and the AFO's comfort was rated with 1.9±0.3. Statistical differences were found between the wear time reported by the patients and the wear time derived from the TS (p=0.005). Additionally, a significant correlation between the AFO comfort and the wear time derived from the TS was found (r = -0.81; p=0.001). No significant correlation was found between pain and wear time.
Conclusions
Conclusions: As can be expected, patients who found the AFO more comfortable were the ones who wore the orthosis for longer periods. The wear time recorded by the TS was significantly lower compared to the self-reports. This might be due to a social desire bias, overestimating the amount of hours of wearing the AFO as we asked the patients to wear it as often as possible. Secondly, patients might have trouble to accurately recall the amount of wear hours, thereby inducing an overestimation of wear time. As the reliability of self-reported measures seems to be questionable, such data should be interpreted with care. 
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Background: Osteoarthritis and soft tissue pathology are diseases that produce important pain and disability in many patients. Some studies support that the low-dose radiotherapy may be effective in refractory diseases. Objectives: The main objective of this study is to evaluate whether the treatment with radiotherapy is long-term effective to reduce the pain in osteoarthritis and soft tissue pathology. The secondary objective is to evaluate the analgesic requirements before and after the treatment. Methods: A prospective and observational study was designed. 38 patients were included. 53 different pathologies were treated including knee osteoarthritis, trochanteric bursitis, calcinosis, rizartrosis, pyramidal syndrome, rotatory cuff pathology and shoulder osteoarthritis, plantar fasciitis, epicondylitis, hand osteoarthritis, tibialis posterior tendonitis, ankle osteoarthritis, hip osteoarthritis and hand tendonitis. All these pathologies did not respond to conventional therapy (non steroidal antiinflamatory drugs, rehabilitation or infiltrations). Initially, the patients received a treatment of radiotherapy with a dose of 6 Gray divided in 6 sessions during 2 weeks. The patients that did not respond after 6 weeks received a second treatment with the same characteristics. The modification in Visual Analogic Scale (VAS) of pain was evaluated as well as analgesic intake before and after the treatment. Results: No side effects were observed. 92% were women and 8% men. Mean age was 66,82, standard deviation (SD) : 12,97 (42-89) . 44 locations responded to one treatment and 19 needed a second one. The mean VAS prior treatment was 7,38, SD: 1,49, (10-4). Mean VAS after the first treatment was 3,81 SD: 2,84 (9-0). The mean VAS after the first treatment in locations that received 2 treatments was 6,65 SD: 1,46 (9-5), and mean VAS after the second one was 4,56 DE: 2,66 (8-1). By pathology, the difference in means was: 4,8 in knee osteoarthritis (N=11), 4,78 in trochanteric bursitis (N=10), 5 in calcinosis (N=3), 5,33 rizartrosis (N=8), 4 in pyramidal syndrome (N=2), 3,87 in rotatory cuff pathology and shoulder osteoarthritis (N=6), 6 in plantar fasciitis (N=1), 7 in epicondylitis (N=1), 3,22 in hand osteoarthritis (N=11), 6 in tibialis posterior tendonitis (N=2), 4 in ankle osteoarthritis (N=2), 2 in hip osteoarthritis (N=1) and 2,2 in hand tendonitis (N=5). Until November 2016, 12 patients (17 pathologies) were followed-up for 6 months. The mean VAS before treatment of these pathologies was 7,29 SD: 1,21; (9-4). After 6 months mean VAS reduced to 1,47 SD: 1,42; (5-0).
